The global Electroporation Instruments Market is estimated to be valued at US$ 242.41 Bn in 2023 and is expected to exhibit a CAGR of 4.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Electroporation instruments are used to applied brief high-voltage pulses to create temporary pores in cell membranes through which drugs or DNA can be introduced into the cell. These instruments help in gene transfer and drug delivery for cancer treatment using techniques such as irreversible electroporation and electrochemotherapy. Electroporation instruments find applications in research, biomedical science including genetic engineering and cell biology, and gene therapy. The advantages of electroporation over viral and chemical methods include high transfection efficiency, flexibility in the choice of target cells, and ease of optimization and scale-up for clinical applications.
Market key trends:
The major trend driving the growth of electroporation instruments market is increasing adoption of irreversible electroporation (IRE) technique for cancer treatment. IRE uses short pulses of high voltage to form permanent nanopores in the cell membrane, killing cells by disrupting their homeostasis without generating heat like other ablation techniques. IRE has gained popularity in treatment of tumors located close to critical structures as it helps in tissue preservation by avoiding collateral damage. The use of IRE provides painless, incisionless and blood flow-preserving tissue ablation with minimal adverse effects, thereby fueling the demand for electroporation instruments globally.
Threat of new entrants: Low threat as electroporation instruments market requires heavy R&D investment and presence of established players with strong brand image.
Bargaining power of buyers: Moderate power as electroporation instruments have applications across biotech and pharmaceutical industry creating demand.
Bargaining power of suppliers: Moderate power as key components in instruments are supplied by limited specialized manufacturers globally.
Threat of new substitutes: Low threat as electroporation technique is proven efficient for various applications with no close substitutes available.
Competitive rivalry: High rivalry between major players to gain market share through new product launches, collaborations and expansions.
Global Electroporation Instruments Market Demand is expected to witness high growth, exhibiting a CAGR of 4.4% over the forecast period, due to increasing adoption in gene therapies and cell therapies.
Regional analysis: North America dominates the electroporation instruments market currently owing to presence of leading biotech companies and research institutes. Asia Pacific is expected to witness fastest growth over the forecast period supported by increasing biotech investments and production facilities in countries like China and India.
Key players operating in the electroporation instruments market incorporate Bio-Rad Laboratories, Inc, Thermo Fisher Scientific Inc., BTX ( a division of Harvard Bioscience), Celetrix, LLC., Gamma Biosciences, Merck KgaA, Eppendorf SE, MaxCyte, Inc. BEX CO.,LTD., Lonza, Altogen Biosystems, Ala Scientific Instruments, Inc., BioEra Life Sciences Pvt. Ltd., and Ichor Medical Systems. Key players are focusing on new product launches to consolidate their market share. For instance, Bio-Rad Laboratories launched Bio-Rad Gene Pulser Xcell electroporation systems with improved features in 2021.